ARCA biopharma Announces 2023 Financial Results


WESTMINSTER, Colo., Feb. 01, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2023 financial results and provided a corporate update.

More:
ARCA biopharma Announces 2023 Financial Results

Related Posts